Skip to main content

FGFR Inhibitor Debio 1347 and Fulvestrant in Treating Patients with FGFR-Amplified Endocrine Receptor Positive Metastatic Breast Cancer

Trial Status: Active

This phase Ib / II trial studies the side effects and best dose of FGFR inhibitor Debio 1347 when given together with fulvestrant and to see how well they work in treating patients with FGFR-amplified endocrine receptor positive breast cancer that has spread to other places in the body (metastatic). FGFR inhibitor Debio 1347 may block some receptors that needed for cell growth. Estrogen can cause the growth of breast cancer cells. Drugs, such as fulvestrant, may lessen the amount of [hormone] made by the body. Giving FGFR inhibitor Debio 1347 and fulvestrant may work better in treating patients with FGFR-amplified endocrine receptor positive breast cancer.

Inclusion Criteria

  • Written informed consent and authorization obtained from the subject/Health Insurance Portability and Accountability Act (HIPAA)-appointed legal representative prior to performing any protocol-related procedures including screening evaluations
  • Patients with metastatic histologically or cytologically confirmed invasive breast cancer
  • Female patients of postmenopausal status; postmenopausal status will be defined as following: * Age >= 60 years * Age < 60 years and 12 months of amenorrhea plus follicle stimulating hormone and plasma estradiol levels within postmenopausal range by local laboratory assessment in the absence of oral contraceptive pills, hormone replacement therapy, or gonadotropin-releasing hormone (GnRH) agonist or antagonist * Prior bilateral oophorectomy
  • Pre or perimenopausal women allowed with the addition of goserelin
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 -1
  • Tumor must be estrogen receptor and/or progesterone receptor positive (i.e. hormone receptor positive [HR+] and HER-2 negative as defined by the American Society of Clinical Oncology/College of American Pathologists [ASCO-CAP] guidelines: HR+ is defined as expression of ER and/progesterone receptor [PR] in >= 1% of cells, or HR+ by local laboratory or regional definition; HER2− is defined as a HER2 immunohistochemistry [IHC] score of 0 or 1+, or an IHC score of 2+ accompanied by a negative fluorescence, chromogenic, or silver in situ hybridization test indicating the absence of HER2 gene amplification, or a HER2/CEP17 ratio of < 2.0, or local clinical guidelines
  • Tumors must have FGFR amplifications as determined by a Clinical Laboratory Improvement Act (CLIA) certified laboratory assay; patients with FGFR amplifications co-occurring with 11q amplification (CCND1, FGF3,4, 19 amplifications) are also eligible
  • Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 or pure lytic or mixed lytic-blastic bone lesions
  • No more than 1 prior chemotherapy regimen in the metastatic setting for the phase 2 portion; patients in the phase 1 portion could have received any number of prior lines of therapy
  • Willing to undergo a new core or excisional biopsy from a metastatic, not previously irradiated tumor lesion during screening
  • Life expectancy of greater than 3 months
  • Archival tumor (up to 10 unstained slides) will be obtained, whenever available for additional biomarker analyses
  • White blood cell (WBC) count of > 3000/ul
  • Absolute neutrophil count (ANC) > 1000/ul
  • Platelets > 100,000/ul
  • Hemoglobin > 9.0 g/dl
  • Corrected calcium value =< 1.1 x upper limit of normal (ULN)
  • Total bilirubin =< 1.5 x ULN (upper limit of normal) except subject with documented Gilbert's syndrome (=< 5 x ULN) or liver metastasis, who must have a baseline total bilirubin =< 3.0 mg/dL
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULN
  • Alkaline phosphatase (ALP) =< 2.5 x ULN or =< 5.0 x ULN for patients with bone metastases
  • Gamma-glutamyltransferase =< 2.5 x ULN
  • Albumin >= 2.5 g/dL
  • Phosphate =< 1.1 x ULN
  • Prothrombin time (PT) and/or prothrombin time international normalized ratio (PT-INR) and/or activated partial thromboplastin time (APTT) =< 1.3 x ULN
  • Serum creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min on the basis of the Cockcroft−Gault glomerular filtration rate estimation
  • Patients with “treated and stable” brain lesions for a duration of > 4 weeks may be enrolled
  • Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication and agree to use effective contraception; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject

Exclusion Criteria

  • Prior fulvestrant for metastatic breast cancer will be allowed for phase 1 portion but not for the phase 2 portion
  • History of hypersensitivity to any of the excipients in the Debio 1347 formulation (lactose hydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, sodium lauryl sulfate, and magnesium stearate)
  • Other malignancies requiring active treatment in the last 6 months
  • Brain tumors and/or brain metastases unless they are asymptomatic, stable on recent imaging (not dated more than 30 days from the inclusion date) and have not required active treatment in the last 6 months
  • History and/or current evidence of endocrine alteration of calcium-phosphate homeostasis
  • History of myocardial infarction or stroke within 6 months, congestive heart failure greater than New York Heart Associate (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment or family history of sudden death from cardiac-related causes
  • Baseline Fridericia's corrected QT (QTcF) interval greater than 470 msec (female) or greater than 450 msec (male), history of congenital long QT syndrome, the presence in the screening electrocardiography (ECG) of a conduction abnormality that in the opinion of the investigator would preclude safe participation in this study
  • Concomitant use of a drug with a known risk of corrected QT interval (QTc) prolongation
  • Current anticoagulation therapy with therapeutic doses of warfarin (low-dose warfarin =< 1 mg/day or low molecular-weight heparin are permitted
  • History and or current evidence of ectopic mineralization/calcification including but not limited to the soft tissue, kidneys, intestine, myocardium and lung with the exception of calcified lymph nodes and asymptomatic coronary calcification
  • Concomitant use of high dose systemic steroids and other drugs such as calcitonin preparations, active vitamin D3 preparations, estrogen preparations, selective estrogen receptor modulators, vitamin K2 preparations, parathyroid hormones, phosphorus absorbers; Note, inhaled, topical steroids and low tapering doses of steroid especially in patients treated recently for brain metastases will be included
  • Corneal disease, such as bullous or band keratopathy, corneal desquamation, keratitis, corneal ulcer, or keratoconjunctivitis
  • Known infection requiring the systemic use of, for example, an antibiotic or antiviral agent
  • Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Known untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of study entry
  • History of organ, bone marrow, or stem cell transplantation
  • Pregnant or lactating woman (any woman of childbearing potential who has menstruated within the year prior to enrolment will undergo pregnancy testing within 72 hours prior to receiving the first dose of study medication)
  • Women of childbearing potential or men who are unwilling to use an appropriate method of contraception during the study period and for 6 months after completing treatment with Debio 1347; oral or injectable contraceptive agents cannot be the sole method of contraception; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
  • Poorly controlled diabetes mellitus or hypertension (e.g., systolic > 180 mmHg or diastolic > 100 mmHg)
  • Inability or unwillingness to swallow oral medications
  • Clinically significant gastrointestinal abnormality that would affect the absorption of drug such as gastrointestinal dysfunction, malabsorption syndrome, major resection of the small bowel or total gastrectomy or inflammatory bowel disease
  • Uncontrolled hydropericardium
  • Chemotherapy or radiotherapy within 14 days prior to starting study treatment; in case of monoclonal antibodies/biologics, within 28 days prior to starting study treatment
  • Administration of investigational agents within 28 days prior to treatment initiation
  • Major surgery and surgery for brain metastases within 28 days prior to screening start; of note, intravenous port placement is not considered as a major surgery
  • Not recovered from adverse events (AE)s or toxicities due to previous treatments to a grade 1 or less specified in National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 excepting, albumin (< 2.5 g/dL), AST and ALT in patients with liver metastases (> 5 x ULN) alkaline phosphatase (ALP) in patients with bone metastases (> 5 x ULN) and alopecia
  • Prior use of a drug targeting FGF or FGFR; patients previously treated with medications that affect FGFR signaling as a secondary target (e.g., multi-tyrosine kinase inhibitors that primarily inhibit VEGF, but to a lesser extent also affect FGFR signaling) can be considered after discussion with the principal investigator
  • Currently under alcohol or drug abuse rehabilitation or treatment program
  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements

New York

New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Komal Jhaveri
Phone: 646-888-5145


I. To determine the safety, tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of FGFR inhibitor Debio 1347 (Debio 1347) plus fulvestrant in patients with estrogen receptor (ER)+/HER2-/FGFR amplified metastatic breast cancer. (Phase I)

II. To investigate the anti-tumor activity of Debio 1347 in combination with fulvestrant in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer as defined as clinical benefit rate (clinical benefit rate [CBR]: objective response rate plus stable disease >= 24 weeks). (Phase II)


I. To obtain a preliminary assessment of the anti-tumor activity (CBR and overall response rate [ORR]) of Debio 1347 in combination with fulvestrant in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer. (Phase I)

II. To further characterize the safety and tolerability of Debio 1347 in combination with fulvestrant in patients with ER+/HER2-/FGFR- amplified metastatic breast cancer. (Phase II)

III. To determine the overall response rate (ORR), time to progression (TTP), progression-free survival (PFS) and overall survival (OS) for the combination of Debio 1347 with fulvestrant in patients with ER+/HER2-/FGFR- amplified metastatic breast cancer. (Phase II)


I. To measure the pharmacokinetic (PK) parameters of Debio 1347 in combination with fulvestrant. (Phase I and Phase II)

II. To measure pharmacodynamic biomarkers of FGFR inhibition. (Phase I and Phase II)

III. To make an assessment of biomarkers of response and/or resistance from archival tissue and fresh tumor biopsies (using next generation sequencing, fluorescence in situ hybridization [FISH], protein and messenger ribonucleic acid [mRNA] expression) and plasma (cell-free deoxyribonucleic acid [DNA]) and correlate with clinical benefit. (Phase I and Phase II)

OUTLINE: This is a phase Ib, dose-escalation study of FGFR inhibitor Debio 1347 followed by a phase II study.

Patients receive fulvestrant intramuscularly (IM) on days 1, 15, and 28 of cycle 1 and on day 1 of subsequent cycles. Patients also receive FGFR inhibitor Debio 1347 orally (PO) daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 2-4 weeks, and then every 12 weeks thereafter.

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Komal Jhaveri

  • Primary ID 17-379
  • Secondary IDs NCI-2017-02427
  • ID NCT03344536